e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
Multidrug-resistant and extensively drug-resistant tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Adverse drug reactions in South African patients being treated for XDR-TB
K. Shean, M. Badri, G. Symons, E. Pietersen, L. Page-Shipp, A. Burns, P. Baitiswe, M. Grobusch, P. Willcox, A. Zumla, K. Dheda (Cape Town, Johannesburg, Kimberley, South Africa; , United Kingdom)
Source:
Annual Congress 2010 - Multidrug-resistant and extensively drug-resistant tuberculosis
Session:
Multidrug-resistant and extensively drug-resistant tuberculosis
Session type:
Oral Presentation
Number:
353
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Shean, M. Badri, G. Symons, E. Pietersen, L. Page-Shipp, A. Burns, P. Baitiswe, M. Grobusch, P. Willcox, A. Zumla, K. Dheda (Cape Town, Johannesburg, Kimberley, South Africa; , United Kingdom). Adverse drug reactions in South African patients being treated for XDR-TB. Eur Respir J 2010; 36: Suppl. 54, 353
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Death rates in patients during and after MDR-TB treatment in a semi rural area of South Africa
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea
Source: Eur Respir J, 54 (5) 1900811; 10.1183/13993003.00811-2019
Year: 2019
Adverse effects of treatment in HIV-associated tuberculosis patients in Iran
Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Year: 2011
Adverse drug reactions to second line anti tuberculosis drugs: A prospective study in Mumbai, India
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
XDR-TB in South Africa: from clinical management to public-health action
Source: Annual Congress 2011 - PG12 TB-PAN-NET Multidrug-resistant and extensively drug-resistant tuberculosis: update on clinical management
Year: 2011
A follow up Study of TB patients put on DOTS from South India
Source: International Congress 2017 – Clinical challenges in chronic lung diseases
Year: 2017
Adverse effects of MDR-TB treatment with a standardized regimen: A report from Iran
Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Year: 2010
The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?
Source: Eur Respir J, 50 (2) 1700753; 10.1183/13993003.00753-2017
Year: 2017
Primary drug resistance in HIV/tuberculosis patients in two large cities of Siberia
Source: International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA)
Year: 2016
Treatment outcomes for multidrug-resistant tuberculosis (MDR-TB) patients in Africa
Source: Annual Congress 2011 - Multidrug-resistant tuberculosis
Year: 2011
The incidence of adverse reactions in anti-tuberculosis chemotherapy in S-W Romania
Source: Annual Congress 2011 - Clinical challenges in tuberculosis
Year: 2011
Prognosis and outcome in patients with extremely drug resistant tuberculosis from the Western Cape province, South Africa
Source: Annual Congress 2008 - Outcomes of tuberculosis treatment
Year: 2008
Culture conversion rates of multi-drug resistant (MDR-TB) patients treated in the community versus an inpatient setting in a rural area of the Western Cape (WC) of South Africa
Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Year: 2012
Adverse events in patients with MDR TB, treated by three types of the chemotherapy regimens
Source: International Congress 2019 – Tuberculosis: treatment and management
Year: 2019
Adverse effects among MDR/XDR TB patients with viral hepatitus appearing during TB chemotherapy
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020
Spectrum of adverse drug reactions during MDR TB treatment
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Smoking and treatments among asthma patients in South Korea
Source: Annual Congress 2011 - Smoking-related diseases and smoking cessation
Year: 2011
Adverse reaction of TB treatment with 2nd line drugs in a tuberculosis TB dispensary
Source: Eur Respir J 2004; 24: Suppl. 48, 648s
Year: 2004
Adverse reactions to bupropion: fourteen cases reported in a French regional pharmacovigilance center. Impact on smoking withdrawal
Source: Eur Respir J 2005; 26: Suppl. 49, 155s
Year: 2005
Drug resistance and HIV rates are high in Eastern European patients with Tuberculosis in a South East London Hospital
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept